References
- Schwering I, Bräuninger A, Klein U, . Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2003;101:1505–1512.
- Küppers R, Rajewsky K, Zhao M, . Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci USA 1994;91:10962–10966.
- Kanzler H, Kuppers R, Hansmann ML, . Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 1996;184:1495–1505.
- Marafioti T, Hummel M, Foss HD, . Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 2000;95:1443–1450.
- Farrell K, Jarret RF. The molecular pathogenesis of Hodgkin lymphoma. Histopathology 2011;58:15–25.
- McCune RC, Syrbu SI, Vasef MA. Expression profiling of transcription factors Pax-5, Oct-1, Oct-2, BOB.1, and PU.1 in Hodgkin's and non-Hodgkin's lymphomas: a comparative study using high throughput tissue microarrays. Mod Pathol 2006;19:1010–1018.
- Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009;9:15–27.
- Schwering I, Bräuninger A, Distler V, . Profiling of Hodgkin's lymphoma cell line L1236 and germinal center B cells: identification of Hodgkin's lymphoma-specific genes. Mol Med 2003;9:85–95.
- Kurosaki T, Hikida M. Tyrosine kinases and their substrates in B lymphocytes. Immunol Rev 2009;228:132–148.
- Gauld SB, Cambier JC. Src-family kinases in B-cell development and signalling. Oncogene 2004;23:8001–8006.
- Taborelli M, Tibiletti MG, Martin V, . Chromosome band 6q deletion pattern in malignant lymphomas. Cancer Genet Cytogenet 2006;165:106–113.
- Kozłowska A, Jagodziński PP. Inhibition of DNA methyltransferase activity upregulates Fyn tyrosine kinase expression in Hut-78 T-lymphoma cells. Biomed Pharmacother 2008;62:672–676.
- Kulathu Y, Hobeika E, Turchinovich G, Reth M. The kinase Syk as an adaptor controlling sustained calcium signalling and B-cell development. EMBO J 2008;27:1333–1344.
- Dykstra ML, Longnecker R, Pierce SK. Epstein-Barr virus coopts lipid rafts to block the signalling and antigen transport functions of the BCR. Immunity 2001;14:57–67.
- Longnecker R. Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence? Adv Cancer Res 2000;79:175–200.
- Winberg GL, Matskova F, Chen P, . Latent membrane protein 2A of Epstein Barr virus binds WW domain E3 protein-ubiquitin ligases that ubiquinate B-cell tyrosine kinases. Mol Cell Biol 2000;20: 8526–8535.
- Rovedo M, Longnecker R. Epstein-Barr virus latent membrane protein 2A preferentially signals through the Src family kinase Lyn. J Virol 2008;82:8520–8528.
- Jarret RF. Viruses and Hodgkin's lymphoma. Ann Oncol 2002;13:23–29.
- Marafioti T, Pozzobon M, Hansmann ML, . Expression of intracellular signalling molecules in classical and lymphocyte predominance Hodgkin disease. Blood 2004;103:188–193.
- Swerdlow SH, Campo E, Harris NL, . WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
- Pozzobon M, Marafioti T, Hansmann ML, . Intracellular signalling molecules as immunohistochemical markers of normal and neoplastic human leucocytes in routine biopsy samples. Br J Haematol 2004;124:519–533.
- Hosmer DW, Lemeshow S. Applied survival analysis: regression modeling of time to event data. New York: John Wiley & Sons; 1999.
- Royston P, Sauerbrei W. Multivariable model-building: a pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables. Chichester: John Wiley & Sons; 2008.
- Royston P, Reitz M, Atzpodien J. An approach to estimating prognosis using fractional polynomials in metastatic renal carcinoma. Br J Cancer 2006;94:1785–1788.
- Browne P, Petrosyan K, Hernandez A, Chan JA. The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma. Am J Clin Pathol 2003;120:767–777.
- Torlakovic E, Tierens A, Dang HD, . The transcription factor PU.1, necessary for B-cell development, is expressed in lymphocyte predominance, but not classical Hodgkin's disease. Am J Pathol 2001;159:1807–1814.
- Choi YL, Bocanegra M, Kwon MJ, . LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res 2010;70:2296–2306.
- Stettner MR, Wang W, Nabors LB, . Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells. Cancer Res 2005;65:5535–5543.
- Contri A, Brunati AM, Trentin L, . Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 2005;115: 369–378.
- Diepstra A, van Imhoff GW, Schaapveld M, . Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients. J Clin Oncol 2009;27:3815–3821.
- Marafioti T, Pozzobon M, Hansmann ML, . Expression pattern of intracellular leukocyte-associated proteins in primary mediastinal B cell lymphoma. Leukemia 2005;19: 856–861.
- Young RM, Hardy IR, Clarke RL, . Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. Blood 2009;113:2508–2516.
- Chen L, Monti S, Juszczynski P, . SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008;111:2230–2237.
- Friedberg JW, Sharman J, Sweetenham J, . Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578–2585.
- Davis RE, Ngo VN, Lenz G, . Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010;463: 88–92.
- Irish JM, Czenwinski DK, Nolan GP, Levy R. Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood 2006;108: 3135–3142
- Rinaldi A, Kwee I, Taborelli M, . Genomic and expression profiling identifies the B-cell associated tyrosine kinase SYK as a possible therapeutic target in mantle cell lymphoma. Br J Haematol 2006;132:303–316.
- Leseux L, Hamdi SM, al Saati T, . Syk-dependent mTOR activation in follicular lymphoma cells. Blood 2006;108: 4156–4162.
- Lu J, Lin W, Chen S, . Syk tyrosine kinase mediates Epstein-Barr virus latent membrane protein 2A-induced cell migration in epithelial cells. J Biol Chem 2006;281:8806–8814.
- Juric D, Lacayo NJ, Ramsey MC, . Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. J Clin Oncol 2007;25:1341–1349.
- Lerma EI, Nguyen VA, Wang T, . Novel compounds with antiproliferative activity against imatinib-resistant cell lines. Mol Cancer Ther 2007;6:655–666.
- Huang F, Reeves K, Han X, . Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 2007;67:2226–2238.